Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 +/- Carboplatin in Refractory Solid Tumors
NCT02941523Phase 2Completed
- Sponsor
- Noxopharm Limited
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idronoxil in prostate cancer (PCa), lung cancer, breast cancer and 2 more (2 cohorts), sponsored by Noxopharm Limited. Primary endpoints: Dose Limiting Toxicity at 7 months and Treatment Emergent Adverse Events at 8 months. Started Mar 2017; status: completed.
02
Drugs
idronoxil
03
Conditions
prostate cancer (PCa)lung cancerbreast cancerovarian cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02941523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941523.